Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Death in Lebanon

 
The Ministry of Public Health launched in collaboration with the national committee for the prevention of cardiovascular diseases and Yaduna -Women Heart Health Center the National campaign for the early detection and prevention of cardiovascular diseases under the title “Don’t wait, your heart can’t wait”, during a conference held under the patronage and in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani at the Adnan Kassar Edifice in Bir Hassan.
 
The Head of Primary health care Department at Health Ministry Dr. Randa Hamadeh made a presentation of the path of the national campaign. “This campaign that starts today will last for three months until the end of April. It will kick off from the national network of primary health care centers located across all the Lebanese territory and aims at providing services to citizens, i.e. free cardiovascular examinations for men and women,”Dr. Hamadeh added.
 
The Chairperson of Yaduna foundation Wafaa Sleiman delivered a statement in which she noted that the increasing number of women who underwent an early testing at the Women Heart Health Center, and the detection of many cases of cardiovascular diseases contributed greatly in the treatment of these cases, and led us to activate the prevention and awareness actions across all the Lebanese territory.
 
Hasbani

In a statement, Hasbani noted that the non-communicable diseases cause the death of 38 million people each year, 28 million death cases of which occur in low- and middle-income countries.

“Non-communicable diseases threaten the progress towards achieving the Millennium Development Goals. Poverty and such diseases are highly correlated and it is expected that the rapid growth of these diseases hinder poverty alleviation initiatives in low-income countries, in particular by increasing household costs associated with healthcare services,” Hasbani added.
 
Hasbani highlighted that this activity complements all these efforts, especially that it is integrated with that of Yaduna - Women Heart Health Center, knowing that the primary healthcare brings together all sectors to provide best services to citizens.(Read more...)
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
D10BA01 A-CNOTREN G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,526,524 L.L
D10AD01 A-RET G Tretinoin - 0.05% 0.05% Cream 335,961 L.L
N02BE51 A.B.C NIGHT G Paracetamol - 500mg, Diphenhydramine HCl - 25mg Tablet, film coated 260,152 L.L
N02BE51 A.B.C.-COLD G Paracetamol - 500mg, Chlorphenamine maleate - 4mg, Phenylephrine HCl - 5mg Tablet, film coated 534,977 L.L
B01AC06 A.S HEART G Acetylsalicylic acid - 81mg 81mg Tablet, enteric coated 148,463 L.L
N05AX12 ABILIFY MAINTENA B Aripiprazole - 400mg 400mg Injectable powder for suspension, prolonged release+solvent 29,491,998 L.L
N05AX12 ABIPREX 10 G Aripiprazole - 10mg 10mg Tablet 1,075,074 L.L
N05AX12 ABIPREX 15 G Aripiprazole - 15mg 15mg Tablet 1,075,074 L.L
L02BX03 ABIRATERONE ACETATE NEAPOLIS G Abiraterone acetate - 250mg 250mg Tablet 75,418,662 L.L
L02BX03 ABIRATERONE ACETATE SPC G Abiraterone acetate - 250mg 250mg Tablet, film coated 73,748,373 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet 45,056,853 L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet 45,056,853 L.L
L01CD01 ABRAXANE BioTech Paclitaxel Albumin- bound - 5mg/ml 5mg/ml Injectable powder for dispersion 17,850,751 L.L
L02BX03 ABREMIA G Abiraterone acetate - 250mg 250mg Tablet 77,478,802 L.L
L02BX03 ABREMIA G Abiraterone acetate - 250mg 250mg Tablet L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
J07BX05 ABRYSVO B RSV subgroup A stabilized perfusion F antigen 60mcg - 60mcg, RSV subgroup B stabilized perfusion F antigen 60mcg - 60mcg, Glycoprotein F stabilized in the perfusion conformation - Injectable powder + solvent 22,650,721 L.L
D10BA01 ABSORICA LIDOSE G Isotretinoin - 16mg 16mg Capsule, hard 1,827,045 L.L
N02AB03 ABSTRAL B Fentanyl (citrate) - 200mcg 200mcg Tablet 5,261,143 L.L
N02AB03 ABSTRAL B Fentanyl (citrate) - 100mcg 100mcg Tablet 3,419,743 L.L
N07BB03 ACAMPROSATE BIOGARAN G Acamprosate - 333mg 333mg Tablet, gastroresistant 3,641,813 L.L
V01AA ACARIZAX 12 SQ-HDM ORAL LYOPHILISATE B Allergen extracts - 12 SQ-HDM Tablet, lyophilised 9,366,451 L.L
R05CB01 ACC LONG G N-acetylcysteine - 600mg, Vitamin C - 75mg 600mg Tablet, effervescent 286,238 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 400mg 400mg Tablet, coated 615,480 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 200mg 200mg Tablet, coated 464,970 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
S01EC01 ACETAZOLAMIDE G Acetazolamide - 250mg 250mg Tablet 1,001,163 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026